KAER Biotherapeutics Corporation

KAER focuses on high dose delivery of aerosolized drugs for serious and life-threatening respiratory disorders within clinical settings such as ICU, PICU, surgical suites and emergency rooms. Inadequate deposition of aerosolized therapeutics in the distal lungs is associated with treatment failure. The 40% mortality rate of patients from respiratory distress is unacceptable. To address these issues, KAER developed two novel medical devices. AeroPulsR and SUPRAER enable liquids containing high concentrations of small and oligomeric molecules to be aerosolized and delivered as either aqueous or solid-phase aerosols, respectively. These devices are suitable for deposition in the distal lungs of patients of all ages, as well as for animal health applications. Albeit acute respiratory distress affects patients of all ages, KAER’s first clinical study focuses on the delivery of surfactant aerosol to pediatric patients aged 6-12 years with respiratory distress resultant from pneumonia.